CLBS12
- Generic Name
- CLBS12
- Drug Type
- Biotech
- Background
CLBS12 is a GCSF-mobilized autologous cell therapy derived from CD34+ cells being investigated for the treatment of Buerger’s disease.
Study of Intracoronary CD34+ Cell Administration in Patients With Early Coronary Atherosclerosis
Phase 1
Completed
- Conditions
- Atherosclerosis, Coronary
- Interventions
- Drug: Granulocyte Colony-Stimulating Factor (G-CSF)
- First Posted Date
- 2018-03-20
- Last Posted Date
- 2022-02-07
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 21
- Registration Number
- NCT03471611
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI)
Phase 2
Completed
- Conditions
- Critical Limb IschemiaBuerger DiseaseThromboangiitis ObliteransAtherosclerosis Obliterans
- Interventions
- Drug: SOC
- First Posted Date
- 2015-07-17
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Lisata Therapeutics, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT02501018
- Locations
- 🇯🇵
Oita Oka Hospital, Oita, Japan
🇯🇵Asahikawa Medical University Hospital - 1-1-1 Higashi-2jou, Midorigaoka, Asahikawa-shi, Japan
🇯🇵Shonan Kamakura General Hospital, Kamakura, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath